The core tension the essay identifies lies in the mismatch between how psychiatrists are trained and how psychiatric practice is governed. Psychiatry is unusual among medical specialties in that its practitioners are explicitly taught to evaluate biological, psychological, and social dimensions of illness simultaneously. A clinician assessing a patient may consider neurochemistry, family history, and housing status in the same encounter. Yet, the authors argue, the dominant frameworks that structure psychiatric work remain oriented toward individual symptom management. Treatment protocols, reimbursement systems, and professional incentives are largely built around the episodic care of discrete patients rather than the population-level conditions, such as poverty, war, and social exclusion, that generate much of the distress clinicians see every day. The result, they suggest, is a discipline whose diagnostic sophistication routinely outpaces its engagement with causes.

The scale of the problem is well documented in the global mental health literature. Treatment gaps for common mental disorders remain enormous in many low- and middle-income countries, where the majority of people with conditions such as depression, anxiety, and psychosis receive no formal care at all. The essay emphasizes that this burden is not distributed evenly. Conflict and forced displacement have disproportionate impacts on psychological wellbeing, and structural inequity, understood as the systematic arrangement of resources and opportunities along lines of wealth, geography, and identity, shapes who becomes ill, who gets treated, and who recovers. In such contexts, the authors contend, a purely clinical response risks treating the symptoms of arrangements that will simply generate new patients tomorrow. Addressing mental health at scale therefore requires attention to the machinery that produces distress, not only the individuals who present with it.

Pragmatic solidarity, as the essay deploys the concept, is the practice of standing with communities rather than merely serving them. Farmer’s formulation, developed through decades of work delivering health care in settings of extreme poverty, insisted that effective medicine in such contexts requires accompanying people in their struggle against the conditions that sicken them, including through advocacy for material change. Applied to psychiatry, this means that the discipline’s obligation does not end at the prescription pad. Psychiatrists, the authors argue, are positioned to engage in structural advocacy, to support community-led models of care, and to demand institutional accountability from the hospitals, universities, funders, and governments that shape mental health systems. The framing is deliberately practical: solidarity is presented not as sentiment but as a set of enactable practices with measurable consequences for health.

A central pillar of the argument concerns how global mental health work is conducted across borders and cultures. The authors contend that effective collaboration requires horizontal partnerships, in which expertise and decision-making authority are genuinely shared rather than flowing in one direction from high-income institutions to lower-income settings. Closely related is the demand for epistemic justice, the recognition that communities experiencing mental distress hold valid knowledge about their own needs and priorities, and that this knowledge should carry weight in the design of programs and research. The essay argues for the centering of community-defined priorities over externally imposed frameworks, a critique aimed at models in which diagnostic categories, intervention packages, and research agendas are developed elsewhere and delivered without meaningful local input. In such models, the authors suggest, even well-intentioned programs can reproduce the very inequities they claim to address.

The essay then moves from principle to practice, illustrating what pragmatic solidarity looks like at three distinct levels: the individual, the institutional, and the policy arena. At the individual level, clinicians can begin by interrogating their own practice, asking how the social circumstances of their patients connect to their symptoms and where their professional voice might be used in support of change. At the institutional level, the authors point to material redistribution as a concrete mechanism, directing resources, training opportunities, and infrastructure toward the communities and institutions that have historically been excluded from them. Institutional accountability also features here, with the implication that organizations engaged in global mental health should be answerable to the populations they serve rather than only to their funders.

Participatory research emerges as another key entry point. Rather than extracting data from communities for analysis and publication elsewhere, participatory approaches involve community members as partners in framing research questions, collecting and interpreting evidence, and determining how findings are used. For psychiatry, a field whose evidence base has been criticized for underrepresenting the populations that bear the greatest global burden of mental illness, this represents both an ethical correction and a scientific opportunity. Research that genuinely reflects community priorities is more likely to produce interventions that people will actually use, and more likely to identify the structural variables, from housing insecurity to exposure to violence, that conventional study designs often treat as background noise rather than objects of inquiry.

Policy engagement completes the picture. The authors argue that psychiatrists have both the standing and the evidence base to advocate for policies that address the social determinants of mental health, and that this advocacy is a legitimate and necessary extension of professional practice rather than a departure from it. Because psychiatric training integrates biological, psychological, and social perspectives, psychiatrists are unusually well placed to translate population-level evidence into policy arguments that policymakers can act upon. The essay’s call to action insists that the discipline move from recognition of structural drivers, which it describes as well documented, to active participation in dismantling them, a shift that requires clinicians and institutions to see advocacy, partnership, and redistribution as core professional activities rather than optional extras.

What gives the essay its urgency is the insistence that pragmatic solidarity is not merely a theoretical framework but a tangible, enactable way of improving global mental health. The authors are careful to ground their argument in the realities of psychiatric work: clinicians face time pressure, resource constraints, and institutional demands that can make engagement beyond the clinic seem impractical. Yet their response is that the alternative, a psychiatry confined to symptom management while the conditions producing those symptoms remain untouched, is itself a form of practical failure, one that guarantees that the global treatment gap will persist. By identifying specific mechanisms, from community partnership and participatory research to material redistribution and policy engagement, the essay aims to lower the barrier between recognition and action, offering psychiatrists a concrete repertoire rather than an abstract ideal.

The broader significance of the argument extends beyond psychiatry to global health more generally. The essay joins a growing body of scholarship that questions whether technical interventions, however sophisticated, can succeed in contexts where the fundamental drivers of ill health are structural. For mental health in particular, where conditions such as depression and trauma are so tightly entangled with conflict, displacement, poverty, and exclusion, the stakes of this debate are especially high. The authors’ contribution is to argue that the profession’s own training, with its integrated attention to biological, psychological, and social dimensions, already contains the intellectual resources needed for a solidarity-oriented practice. What remains, they contend, is the ethical and institutional commitment to act on that training, standing alongside the communities most affected by mental distress and working with them to change the conditions that produce it.

Subject of Research: The role of psychiatrists in practicing pragmatic solidarity to address structural drivers of global mental distress

Article Title: Beyond the clinic: The role of the psychiatrist in practicing pragmatic solidarity

Article References: Berhe, A., Bala, A., Okopie, T., Agwagom, J., Khan, M., & Song, S. J. (2026). Beyond the clinic: The role of the psychiatrist in practicing pragmatic solidarity. PLOS Mental Health, 3(8), e0000705. https://doi.org/10.1371/journal.pmen.0000705

Image Credits: AI Generated

DOI: 10.1371/journal.pmen.0000705

Keywords: psychiatry, global mental health, pragmatic solidarity, Paul Farmer, structural inequity, treatment gap, epistemic justice, community-led care, participatory research, health policy, conflict and displacement, social determinants

The research team, led by Andrew M. Subica of the University of California, Riverside School of Medicine and Shinichi Nagata of the University of Tsukuba, designed the survey around a deceptively simple question: which specific components of public stigma actually predict whether a Japanese adult would be willing to enter treatment? Rather than treating stigma as a single undifferentiated attitude, the investigators broke it into measurable parts using vignette-based methods. Participants read descriptions of individuals experiencing mental disorders and then rated their perceptions along several dimensions: how serious they considered the condition, whether they believed treatment could help, what they thought caused the disorder, how much social distance they wanted from the person, and whether they perceived the individual as dangerous. This decomposition allowed the researchers to trace the statistical fingerprints of each belief onto treatment-seeking willingness, revealing which threads of the stigma fabric matter most.

The methodological design also included a cross-national comparison that gives the Japanese data much of its interpretive power. The researchers compared their Japanese sample with American adults surveyed in the 2018 U.S. General Social Survey, which used comparable vignette-based stigma measures. The comparison exposed a distinctive pattern of Japanese public stigma that differs in important ways from the American profile. Japanese participants rated mental disorders as significantly less serious than their U.S. counterparts did, expressed lower confidence that treatment works and that recovery is possible, and made fewer neurobiological attributions, meaning they were less likely to explain mental illness in terms of brain chemistry or biological causes. At the same time, Japanese respondents reported a greater desire for social distance from people with mental illness, yet paradoxically perceived those individuals as less dangerous than American respondents did.

That combination, high social distancing paired with low perceived dangerousness, is analytically revealing. In the United States, stigma research has often found that perceived dangerousness drives social rejection: people keep their distance because they fear violence or unpredictability. The Japanese pattern suggests a different mechanism at work. The desire for social distance appears less rooted in fear and more embedded in broader social norms around difference, conformity, and the preservation of group harmony, dynamics that cultural psychologists have long described in Japanese society. Whatever its roots, the practical consequence is the same: people with mental illness face exclusion from social life, and the general public internalizes the message that mental illness marks a person as someone to be kept at arm’s length, a message that discourages anyone experiencing symptoms from identifying themselves as a patient.

Perhaps the most consequential finding concerns beliefs about treatment itself. Within the Japanese sample, the single strongest stigma-related predictor of treatment-seeking willingness was the belief that treatment would improve mental disorders. Participants who had faith in the effectiveness of professional care were substantially more willing to seek it. Conversely, two factors independently predicted lower willingness: the belief that mental disorders would improve on their own without treatment, and a greater desire for social distance from people with mental illness. The first of these, treatment pessimism, is particularly troubling because it functions as a self-sealing barrier. If a person believes that psychiatric conditions resolve naturally, or conversely that treatment offers little benefit, then the entire apparatus of professional mental health care becomes irrelevant to their decision-making, and the low perceived treatment need observed in the sample becomes almost a logical inevitability.

Against this backdrop of barriers, the study identified a potential facilitator with unusual promise: mattering. In psychological science, mattering refers to the perception that one is significant to others, that people care about one’s welfare and would notice one’s absence. Participants who reported greater mattering were more willing to seek treatment, an effect that held independently in the regression analyses alongside prior treatment experience, which also predicted greater willingness. The theoretical logic is intuitive. A person who feels that they matter to family, friends, or community has both a motivation to get better and an implicit assurance that seeking help will be met with concern rather than indifference or judgment. Mattering may act as a psychological counterweight to stigma, giving individuals a reason to push through the social costs that disclosure of a psychiatric problem can carry.

Prior treatment experience emerging as a positive predictor deserves attention as well. It suggests that contact with the mental health system, at least for those who have already navigated it, does not reinforce reluctance but instead appears to normalize help-seeking. This aligns with a long tradition in stigma research showing that familiarity with mental illness, whether through personal treatment history or relationships with people who have psychiatric conditions, tends to erode prejudicial attitudes. For policymakers, the implication is that the first encounter with care is the critical bottleneck; once crossed, the path becomes easier. Interventions that lower the threshold of that first encounter, whether through school-based programs, workplace mental health initiatives, or primary care integration, may generate compounding returns.

The authors frame their findings in terms of mental health equity, and the framing is apt. Japan’s treatment gap is not simply a matter of insufficient psychiatrists or insurance coverage; it is a demand-side problem in which the population’s own beliefs suppress the uptake of available services. The study’s identification of modifiable targets, treatment pessimism, desired social distance, and low mattering, converts a diffuse cultural problem into a set of concrete intervention hypotheses. Anti-stigma campaigns in other countries have shown that messages emphasizing recovery and the effectiveness of treatment can shift public attitudes, and the Japanese data suggest that precisely these beliefs, seriousness, treatability, and recovery expectations, are where Japanese public opinion diverges most sharply from more treatment-friendly profiles. Campaigns could also be designed to cultivate mattering, for example by strengthening community and workplace structures that signal to individuals that their struggles are seen and their wellbeing is valued.

There are, of course, limits to what a single cross-sectional survey can establish. The data capture associations at one point in time and cannot prove that stigma beliefs cause low treatment-seeking, though the theoretical coherence of the relationships and their consistency with international literature strengthen the causal plausibility. The cross-national comparison with the U.S. General Social Survey is descriptive rather than a rigorous matched analysis, and vignette methods, while standardized, measure attitudes toward hypothetical cases rather than lived decisions. Still, the study’s national representativeness, its decomposition of stigma into distinct components, and its identification of mattering as a novel facilitator give it unusual practical value. As Japan confronts the mental health consequences of an aging, stressed, and socially isolated society, this research offers something rare: a precise map of the beliefs that keep people away from care, and an evidence-based hint about the social resources that could bring them back.

Subject of Research: Public stigma toward mental illness and its relationship to treatment-seeking willingness in Japan

Article Title: Mental illness stigma and treatment-seeking willingness in Japan: a national survey study

Article References: Subica, A. M., & Nagata, S. (2026). Mental illness stigma and treatment-seeking willingness in Japan: a national survey study. International Journal for Equity in Health. https://doi.org/10.1186/s12939-026-03007-6

Image Credits: AI Generated

DOI: 10.1186/s12939-026-03007-6

Keywords: Japan, mental illness stigma, treatment-seeking willingness, public stigma, mattering, mental health equity, treatment gap, social distance, cross-national comparison, health survey, psychiatry, help-seeking

The scale of the underlying problem is enormous. Hospitalizations related to alcohol use disorder and opioid use disorder contribute to substantial illness and rising costs, collectively amounting to nearly 50 billion dollars in healthcare spending in 2022 alone. Randomized trials have long supported the use of guideline-recommended medications for these conditions, which meaningfully reduce alcohol or opioid use and improve treatment retention among patients with opioid use disorder. Observational studies have also suggested that these medications could reduce acute healthcare utilization, such as emergency department visits and hospital admissions. Against that evidence base, the treatment rates reported in national surveys are strikingly low: in 2025, only about 3 percent of Americans aged 12 years and older with alcohol use disorder reported receiving medication treatment, and only 16 percent of those with opioid use disorder reported receiving medication in the past year.

Pham and colleagues addressed the relationship between medication use and healthcare utilization using a cross-sectional analysis of US adults from the 2022–2023 National Survey on Drug Use and Health, a nationally representative survey that assesses substance use disorders based on formal diagnostic criteria. Their weighted sample represented 57.5 million adults with past-year alcohol use disorder and 2.9 million adults with past-year opioid use disorder. Within that population, only 2 percent of those with alcohol use disorder and 30 percent of those with opioid use disorder reported using medication treatment within the past year. Perhaps the most consequential single number in the analysis is this: among patients who did not receive medication treatment, the mean number of past-year outpatient visits was 3.3. In other words, many untreated patients were already seeing doctors regularly, which suggests that lack of contact with the healthcare system is not the primary barrier keeping them from evidence-based pharmacotherapy.

The utilization findings themselves were nuanced and, at first glance, counterintuitive. In stratified analyses, healthcare utilization was generally more frequent among patients who received medications for alcohol use disorder, but no consistent association emerged for those who received medications for opioid use disorder. In unadjusted analyses of patients with alcohol use disorder, past-year medication use was associated with more emergency department visits, with an incidence rate ratio of 3.10 (95 percent confidence interval 1.98–4.83), more nights hospitalized, with an incidence rate ratio of 4.10 (95 percent confidence interval 2.17–7.75), and more outpatient visits, with an incidence rate ratio of 1.76 (95 percent confidence interval 1.18–2.62). When the analysts controlled for sociodemographic factors and comorbidities, the associations with emergency department visits and nights hospitalized remained statistically significant but attenuated, at 1.91 (95 percent confidence interval 1.19–3.06) and 2.03 (95 percent confidence interval 1.09–3.79) respectively, while the association with outpatient visits was no longer significant at 1.22 (95 percent confidence interval 0.91–1.63).

For patients with opioid use disorder, the picture was different. The only significant adjusted association between medication treatment and healthcare utilization was for nights hospitalized, with an incidence rate ratio of 2.08 (95 percent confidence interval 1.22–3.55). The divergence between the two conditions is one of the study’s most intriguing puzzles, and the cross-sectional design of the dataset precludes any definitive explanation. One possibility is that patients with alcohol use disorder are offered treatment later in the course of their disease, after alcohol-associated chronic medical conditions have already developed that predispose them to higher rates of healthcare utilization. Another possibility is that the findings reflect a genuine differential effect of medication treatment across the two conditions, given that medications for opioid use disorder are generally considered more effective than those for alcohol use disorder. It also remains unknown how utilization differs depending on which specific medication is initiated and whether psychosocial treatments are delivered concurrently across different medical settings.

The demographic profile of who received treatment adds an important layer of interpretation. Adults who received medications were generally older and more socioeconomically disadvantaged than those who did not: they were less often married, less educated, more often unemployed, and had lower incomes. They also carried more medical comorbidities and had greater severity of their alcohol or opioid use disorder. To some extent, this pattern is reassuring, because it indicates that medications are reaching the population with the highest degree of social vulnerability and clinical need—the patients who stand to benefit from them the most. On the other hand, it suggests that patients are often not receiving treatment earlier in their disease course, at a point when intervention could prevent the downstream social and medical consequences of untreated addiction before they accumulate.

That late start may also help explain another persistent problem: extremely poor persistence with these medications. Prior research has documented high rates of discontinuation of medications for alcohol use disorder and limited retention in buprenorphine treatment for opioid use disorder. The greater socioeconomic disadvantage and disease severity observed among treated patients may themselves act as barriers to staying on treatment, compounding the challenge of retention. This points toward structured interventions that address social vulnerability directly—such as care navigation programs that help patients overcome logistical, financial, and coordination obstacles—as potentially necessary complements to medication prescribing if treatment is to be sustained over time.

Several methodological limitations shape how these findings should be read. Because the study is cross-sectional, the timing of medication use relative to healthcare encounters cannot be determined: it is impossible to know whether healthcare encounters preceded or followed medication initiation, so no causal relationship can be ascribed to the observation that patients receiving medications for alcohol use disorder had higher utilization. The utilization outcomes were self-reported and therefore prone to recall bias, a common trade-off in addiction health services research. National surveys like the National Survey on Drug Use and Health rely on self-reported data, but that approach yields reliable population-level prevalence estimates based on formal diagnostic criteria. Administrative data, by contrast, are compromised by selective and non-standardized screening for alcohol and opioid use disorder in many health systems, which makes case ascertainment less reliable. Future studies could explore novel data linkages or health systems with more standardized screening and documentation procedures to close this gap.

A final interpretive caution concerns the meaning of healthcare utilization itself. Even acute utilization is context-dependent and does not inherently represent a negative outcome. For a patient with an acute health condition, presenting to the emergency department may be a desirable outcome rather than a failure, particularly compared with delaying care and risking disease progression. The survey data used in this study cannot identify which healthcare encounters were preventable or directly attributable to alcohol or opioid use disorder, so higher utilization among treated patients cannot be automatically framed as harm or as treatment failure.

What the study cannot do is establish the effect of these medications on healthcare utilization, and the editorial emphasizes that any interpretation must be situated within decades of randomized trial evidence demonstrating meaningful clinical benefit. What the study does provide is a stark reminder of underutilization—even among patients who are already engaged with the healthcare system and seeing clinicians multiple times a year. The path forward, the editorial argues, lies in high-quality hybrid effectiveness-implementation trials that test strategies to increase uptake of medications for alcohol and opioid use disorder across emergency departments, inpatient wards, and outpatient settings, while simultaneously assessing clinical outcomes including subsequent healthcare utilization. With nearly 50 billion dollars in annual spending tied to alcohol- and opioid-related hospitalizations and treatment rates stuck in the single digits for alcohol use disorder, the economic and human stakes of closing that gap could hardly be higher.

Subject of Research: The association between medications for alcohol and opioid use disorder and healthcare utilization among US adults

Article Title: What is the Relationship Between Addiction Medications and Healthcare Utilization?

Article References: Bernstein, E. Y. (2026). What is the Relationship Between Addiction Medications and Healthcare Utilization?. Journal of General Internal Medicine. https://doi.org/10.1007/s11606-026-10885-7

Image Credits: AI Generated

DOI: 10.1007/s11606-026-10885-7

Keywords: alcohol use disorder, opioid use disorder, medication treatment, healthcare utilization, NSDUH, emergency department visits, hospitalization, treatment retention, addiction medicine, health services research, Journal of General Internal Medicine, treatment gap